Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High plasma GFAP level predicts disability accumulation in secondary progressive MS

Publish date:: September 14, 2020

Key clinical point: High blood glial fibrillary acidic protein level is associated with increased risk of restriction to a wheelchair.

Major finding: Overall, approximately 12% of patients with a high glial fibrillary acidic protein level attained an Expanded Disability Status Scale score of 7, compared with about 5% of patients with a low GFAP level.

Study details: A post hoc analysis of 1,405 participants with secondary progressive multiple sclerosis in the EXPAND study.

Disclosures: Study funding was not reported. Dr. Kuhle had no relevant disclosures to report.

Citation:

Kuhle J et al. MSVirtual2020.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,